JP2012092123A5 - - Google Patents

Download PDF

Info

Publication number
JP2012092123A5
JP2012092123A5 JP2011272494A JP2011272494A JP2012092123A5 JP 2012092123 A5 JP2012092123 A5 JP 2012092123A5 JP 2011272494 A JP2011272494 A JP 2011272494A JP 2011272494 A JP2011272494 A JP 2011272494A JP 2012092123 A5 JP2012092123 A5 JP 2012092123A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
use according
administered
composition
brimonidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011272494A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012092123A (ja
Filing date
Publication date
Priority claimed from US10/607,439 external-priority patent/US20040266776A1/en
Application filed filed Critical
Publication of JP2012092123A publication Critical patent/JP2012092123A/ja
Publication of JP2012092123A5 publication Critical patent/JP2012092123A5/ja
Pending legal-status Critical Current

Links

JP2011272494A 2003-06-25 2011-12-13 ストレス関連症状の重症性を軽減し予防する方法 Pending JP2012092123A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/607,439 2003-06-25
US10/607,439 US20040266776A1 (en) 2003-06-25 2003-06-25 Methods of preventing and reducing the severity of stress-associated conditions

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2006517594A Division JP2007524625A (ja) 2003-06-25 2004-06-22 ストレス関連症状の重症性を軽減し予防する方法

Publications (2)

Publication Number Publication Date
JP2012092123A JP2012092123A (ja) 2012-05-17
JP2012092123A5 true JP2012092123A5 (cg-RX-API-DMAC7.html) 2012-12-27

Family

ID=33540268

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006517594A Pending JP2007524625A (ja) 2003-06-25 2004-06-22 ストレス関連症状の重症性を軽減し予防する方法
JP2011272494A Pending JP2012092123A (ja) 2003-06-25 2011-12-13 ストレス関連症状の重症性を軽減し予防する方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2006517594A Pending JP2007524625A (ja) 2003-06-25 2004-06-22 ストレス関連症状の重症性を軽減し予防する方法

Country Status (14)

Country Link
US (6) US20040266776A1 (cg-RX-API-DMAC7.html)
EP (1) EP1638569B1 (cg-RX-API-DMAC7.html)
JP (2) JP2007524625A (cg-RX-API-DMAC7.html)
KR (1) KR20060023575A (cg-RX-API-DMAC7.html)
CN (2) CN1812791A (cg-RX-API-DMAC7.html)
AT (1) ATE539751T1 (cg-RX-API-DMAC7.html)
AU (2) AU2004253500A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0411826A (cg-RX-API-DMAC7.html)
CA (1) CA2530487C (cg-RX-API-DMAC7.html)
DK (1) DK1638569T3 (cg-RX-API-DMAC7.html)
ES (1) ES2376878T3 (cg-RX-API-DMAC7.html)
MX (1) MXPA05013900A (cg-RX-API-DMAC7.html)
TW (1) TWI371276B (cg-RX-API-DMAC7.html)
WO (1) WO2005002580A1 (cg-RX-API-DMAC7.html)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US6726918B1 (en) 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
ES2250504T3 (es) 2000-11-29 2006-04-16 Allergan Inc. Prevencion del rechazo de injerto en el ojo.
US20050048099A1 (en) 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US8410102B2 (en) 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
US20050020600A1 (en) * 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
US20050059744A1 (en) * 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
US7812049B2 (en) * 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
US20100266638A1 (en) * 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US20050244463A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
DK1761266T3 (da) * 2004-05-25 2013-08-05 Galderma Pharma Sa Forbindelser, formuleringer og fremgangsmåder til at behandle eller forebygge inflammatoriske hudsygdomme
US8802128B2 (en) 2006-06-23 2014-08-12 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
WO2008144399A1 (en) * 2007-05-18 2008-11-27 Bausch & Lomb Incorporated COMPLEXES COMPRISING α2-ADRENERGIC RECEPTOR AGONISTS AND COMPOSITIONS
ES2463717T3 (es) * 2007-07-27 2014-05-29 Galderma Laboratories Inc. Compuestos, formulaciones, y métodos para reducir las arrugas, pliegues y flacidez de la piel
US20090061020A1 (en) * 2007-08-31 2009-03-05 Theobald Klaus P Brimonidine Compositions for Treating Erythema
WO2009052071A1 (en) * 2007-10-18 2009-04-23 Allergan, Inc. Treatment of sensorimotor disorders with 4- ( 1- ( 2, 3 -dimethylphenyl) ethyl) -1h-imidaz0le-2 ( 3h) -thione
US8455548B2 (en) 2007-10-18 2013-06-04 Allergan, Inc. Method of treating sensorimotor disorders with alpha-2 adrenergic receptor agonists
US8470337B2 (en) * 2008-03-13 2013-06-25 Allergan, Inc. Therapeutic treatments using botulinum neurotoxin
US8952011B2 (en) 2008-08-01 2015-02-10 Eye Therapies Llc Compositions and methods for the treatment of nasal conditions
US12246013B2 (en) 2008-08-01 2025-03-11 Eye Therapies Llc Vasoconstriction compositions and methods of use
US8293742B2 (en) 2008-08-01 2012-10-23 Alpha Synergy Development, Inc. Preferential vasoconstriction compositions and methods of use
US20100203165A1 (en) * 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of disorders or conditions of the eye
US8987270B2 (en) 2009-07-27 2015-03-24 Eye Therapies Llc Formulations of selective alpha-2 agonists and methods of use thereof
CA2772354A1 (en) * 2009-08-26 2011-03-10 Daniel W. Gil Method of treating compulsive disorders with alpha-2b adrenergic receptor agonists
JP5982287B2 (ja) 2009-11-09 2016-08-31 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 発毛を刺激する組成物および方法
EP2329849B1 (en) 2009-11-18 2015-04-29 Galderma Research & Development Combination of alpha-2 adrenergic receptor agonist and non-steroidal anti-inflammatory agent for treating or preventing an inflammatory skin disorder
US8394800B2 (en) * 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
WO2011075621A1 (en) * 2009-12-17 2011-06-23 Alpha Synergy Development, Inc. Compositions and methods for ophthalmic delivery of nasal decongestants
CA2792649A1 (en) 2010-03-26 2011-09-29 Michael Graeber Improved methods and compositions for safe and effective treatment of telangiectasia
AU2011231543B2 (en) 2010-03-26 2015-01-15 Galderma Research & Development Improved methods and compositions for safe and effective treatment of erythema
US20120073515A1 (en) * 2010-09-28 2012-03-29 Advanced Bionics Corporation Intrathecal needle guide apparatus
EP2444068B2 (en) 2010-10-21 2017-12-06 Galderma S.A. Brimonidine gel composition
US8053427B1 (en) 2010-10-21 2011-11-08 Galderma R&D SNC Brimonidine gel composition
US8445526B2 (en) 2011-02-03 2013-05-21 Glaucoma & Nasal Therapies Llc Compositions and methods for treatment of glaucoma
AU2012280947B2 (en) * 2011-07-14 2016-04-07 Allergan, Inc. Methods for treatment of incontinence associated with sexual activity
HK1218850A1 (zh) 2013-02-15 2017-03-17 Allergan, Inc. 持续药物递送植入物
US8999938B2 (en) 2013-06-21 2015-04-07 Gnt Llc Ophthalmic lipophilic drug delivery vehicle formulations
EP3226972A4 (en) * 2014-12-01 2018-08-08 Achelios Therapeutics, Inc. Methods and compositions for treating migraine and conditions associated with pain
MX2021001645A (es) * 2018-08-29 2021-05-12 Cellix Bio Private Ltd Metodos y composiciones oftalmicas para el tratamiento de trastornos del ojo y enfermedades de la piel.
CN113784712A (zh) 2019-05-01 2021-12-10 克雷西奥生物科技有限公司 治疗瘙痒的方法
CN120938924B (zh) * 2025-10-17 2025-12-16 杭州云柏医药科技有限公司 一种盐酸乌拉地尔注射液及其制备方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5380754A (en) * 1988-02-29 1995-01-10 Virotex Corporation Topical composition enhancing healing of viral lesions
US6323204B1 (en) * 1993-10-13 2001-11-27 Allergan Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
JP3683908B2 (ja) * 1993-10-13 2005-08-17 アラーガン、インコーポレイテッド （２−イミダゾリン−２−イルアミノ）キノキサリン誘導体の使用方法
US6462077B1 (en) * 1993-12-28 2002-10-08 Allergan, Inc. Thromboxane ligands without blood clotting side effects
GB9425211D0 (en) * 1994-12-14 1995-02-15 Ucb Sa Substituted 1H-imidazoles
WO1996025163A1 (en) 1995-02-14 1996-08-22 Board Of Supervisors Or Louisiana State Universityof Agricultural And Mechanical College Through Itsmedical Center Treatment of herpes simplex viruses
US6194415B1 (en) * 1995-06-28 2001-02-27 Allergan Sales, Inc. Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US6576636B2 (en) * 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US20030059471A1 (en) * 1997-12-15 2003-03-27 Compton Bruce Jon Oral delivery formulation
WO1999030690A1 (en) 1997-12-15 1999-06-24 Axia Therapeutics, Inc. Oral delivery formulation
BR9914799A (pt) 1998-10-27 2001-07-10 Alcon Lab Inc Sistema conservante para composições farmacêuticas administráveis topicamente contendo um sabão de ácido graxo/aminoácido
EP1187604A4 (en) * 1999-05-28 2004-02-11 Jeffrey Berlant CONNECTIONS AND METHODS FOR TREATING POST-TRAUMATIC STRESS FAILURES
AU5331200A (en) 1999-06-11 2001-01-02 Ohio State University Research Foundation, The Methods and compositions for treating raynaud's phenomenon and scleroderma
KR100331529B1 (ko) 1999-06-16 2002-04-06 민경윤 난용성 항진균제의 경구투여용 조성물 및 그의 제조 방법
US7160890B2 (en) * 1999-12-02 2007-01-09 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
IN188750B (cg-RX-API-DMAC7.html) 1999-12-04 2002-11-02 Khamar Bakulesh Dr Mafatlal
US6294553B1 (en) * 2000-02-15 2001-09-25 Allergan Sales, Inc. Method for treating ocular pain
US6444681B1 (en) * 2000-06-09 2002-09-03 The Ohio State University Research Foundation Methods and compositions for treating Raynaud's Phenomenon and scleroderma
AU7326901A (en) * 2000-07-14 2002-01-30 Allergan Sales Inc Compositions containing alpha-2-adrenergic agonist components
US6673802B2 (en) * 2000-12-01 2004-01-06 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
ATE446298T1 (de) 2001-11-30 2009-11-15 Osi Pharm Inc Verbindungen, die für adenosin a1 und a3 rezeptoren spezifisch sind, und deren anwendungen
IL147921A0 (en) * 2002-01-31 2002-08-14 Abdulrazik Mohammad A method for treating central nervous system disorders by ocular dosing
US7345065B2 (en) * 2002-05-21 2008-03-18 Allergan, Inc. Methods and compositions for alleviating pain
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US20050020600A1 (en) 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
DK1761266T3 (da) 2004-05-25 2013-08-05 Galderma Pharma Sa Forbindelser, formuleringer og fremgangsmåder til at behandle eller forebygge inflammatoriske hudsygdomme

Similar Documents

Publication Publication Date Title
JP2012092123A5 (cg-RX-API-DMAC7.html)
JP2019516735A5 (cg-RX-API-DMAC7.html)
JP2014515013A5 (cg-RX-API-DMAC7.html)
PH12015502628B1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease
HRP20250119T1 (hr) Kdm1a inhibitor i njegova primjena u terapiji
EA201592256A1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
EA201690287A1 (ru) 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом
EA201690223A1 (ru) Ингибиторы фактора в комплемента на основе производных пиперидинилиндола и их применение
PH12014502363A1 (en) N-aryltriazole compounds as lpar antagonists
JP2013507408A5 (cg-RX-API-DMAC7.html)
PH12014502789A1 (en) N-alkyltriazole compounds as lpar antagonists
ECSP13012812A (es) Formulaciones inmunosupresoras
WO2012099942A3 (en) Methods and compositions for treating metabolic syndrome
EA201592255A1 (ru) Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания
WO2014197345A3 (en) Imidazole derivatives and methods of use thereof for improving the pharmacokinetics of a drug
MX2016008665A (es) Derivado basado en 1,2-naftoquinona y metodo de preparacion del mismo.
MA37455A1 (fr) Utilisation d'un dérivé de pyrazole dans le traitement d'exacerbations aigues d'une maladie pulmonaire obstructive chronique
NZ720328A (en) Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease
JP2009537554A5 (cg-RX-API-DMAC7.html)
EA201300990A1 (ru) Парентеральное введение тапентадола
JP2015510916A5 (cg-RX-API-DMAC7.html)
WO2015000431A9 (zh) 替唑尼特氨基甲酸酯及其在药学中的应用
WO2015116856A3 (en) Farnesoid x receptor antagonists
HK1231390A1 (zh) 用於局部给药的药用组合物
EA201692298A1 (ru) Производные карбоксамидов